Introduction
An estimated 14,480 new cervical cancers and 4,290 cervical cancer deaths will occur in the United States in 2021(1).
About 90% of cervical cancer patients are squamous cell carcinoma. Small cell carcinoma of the cervix (SCCC) is a rare disease accounting for approximately 2–5% of uterine cervix malignancies (2-4)
SCCC have histological features that resemble small cell neuroendocrine
neoplasms of the lung (5,6),is highly invasive and prone to distant metastatic spread and lymph node involvement causing poorer prognosis than other types of cervical cancer (7,8).
Its clinical manifestations and presentations are similar to those of other cervical cancers (9)